Jessica Jiyeong Lin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 42 | 2024 | 5272 | 4.860 |
Why?
|
Lung Neoplasms | 56 | 2024 | 13268 | 4.520 |
Why?
|
Protein Kinase Inhibitors | 33 | 2024 | 5638 | 2.860 |
Why?
|
Protein-Tyrosine Kinases | 12 | 2024 | 2419 | 2.500 |
Why?
|
Carbazoles | 5 | 2024 | 220 | 1.990 |
Why?
|
Proto-Oncogene Proteins | 11 | 2024 | 4492 | 1.920 |
Why?
|
Proto-Oncogene Proteins c-ret | 10 | 2023 | 225 | 1.850 |
Why?
|
Oncogene Proteins, Fusion | 12 | 2024 | 1594 | 1.610 |
Why?
|
Drug Resistance, Neoplasm | 17 | 2024 | 5253 | 1.600 |
Why?
|
Pyrazoles | 14 | 2023 | 1992 | 1.530 |
Why?
|
Receptor Protein-Tyrosine Kinases | 9 | 2023 | 1623 | 1.430 |
Why?
|
Piperidines | 6 | 2024 | 1639 | 1.300 |
Why?
|
Lactams | 7 | 2023 | 154 | 1.280 |
Why?
|
Pyrimidines | 10 | 2024 | 3005 | 1.160 |
Why?
|
Aminopyridines | 8 | 2023 | 564 | 1.060 |
Why?
|
Chylous Ascites | 1 | 2022 | 21 | 0.820 |
Why?
|
Organophosphorus Compounds | 2 | 2024 | 203 | 0.790 |
Why?
|
Chylothorax | 1 | 2022 | 83 | 0.770 |
Why?
|
Lactams, Macrocyclic | 7 | 2023 | 315 | 0.680 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1005 | 0.650 |
Why?
|
Platinum | 1 | 2019 | 219 | 0.610 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1728 | 0.570 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 162 | 0.530 |
Why?
|
Mutation | 24 | 2024 | 29929 | 0.490 |
Why?
|
Protein Kinases | 1 | 2022 | 1608 | 0.480 |
Why?
|
Plasmacytoma | 1 | 2014 | 171 | 0.450 |
Why?
|
Pyridines | 5 | 2023 | 2864 | 0.440 |
Why?
|
Brain Neoplasms | 5 | 2022 | 8981 | 0.410 |
Why?
|
Antineoplastic Agents | 7 | 2024 | 13597 | 0.400 |
Why?
|
Immunotherapy | 4 | 2020 | 4641 | 0.340 |
Why?
|
Acrylamides | 2 | 2024 | 259 | 0.340 |
Why?
|
Humans | 70 | 2024 | 757566 | 0.330 |
Why?
|
Gene Fusion | 2 | 2022 | 354 | 0.320 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2017 | 331 | 0.270 |
Why?
|
Aniline Compounds | 2 | 2024 | 1068 | 0.260 |
Why?
|
Molecular Targeted Therapy | 5 | 2023 | 2796 | 0.260 |
Why?
|
Neoplasms | 5 | 2024 | 21986 | 0.260 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4886 | 0.240 |
Why?
|
Gene Rearrangement | 2 | 2019 | 1125 | 0.210 |
Why?
|
Aged | 21 | 2024 | 167890 | 0.210 |
Why?
|
Solvents | 2 | 2020 | 292 | 0.200 |
Why?
|
Aged, 80 and over | 13 | 2024 | 58558 | 0.200 |
Why?
|
Middle Aged | 22 | 2024 | 219192 | 0.200 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 245 | 0.190 |
Why?
|
Acetonitriles | 1 | 2021 | 54 | 0.190 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1046 | 0.190 |
Why?
|
Medical Oncology | 2 | 2024 | 2308 | 0.180 |
Why?
|
Receptor, trkA | 1 | 2021 | 159 | 0.180 |
Why?
|
Adult | 20 | 2024 | 219725 | 0.180 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 317 | 0.180 |
Why?
|
Retrospective Studies | 11 | 2024 | 79984 | 0.170 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1733 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2021 | 570 | 0.160 |
Why?
|
Male | 22 | 2024 | 358180 | 0.160 |
Why?
|
Female | 26 | 2024 | 389943 | 0.160 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2017 | 2052 | 0.150 |
Why?
|
MicroRNAs | 1 | 2014 | 3780 | 0.150 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6323 | 0.150 |
Why?
|
Young Adult | 8 | 2022 | 58755 | 0.140 |
Why?
|
Oncogene Fusion | 1 | 2017 | 81 | 0.140 |
Why?
|
Cell Line, Tumor | 9 | 2021 | 16881 | 0.140 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2021 | 1445 | 0.140 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 162 | 0.130 |
Why?
|
Tyrosine | 1 | 2020 | 1433 | 0.130 |
Why?
|
Structure-Activity Relationship | 1 | 2021 | 3069 | 0.130 |
Why?
|
Gene Amplification | 1 | 2020 | 1086 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2017 | 2443 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 896 | 0.120 |
Why?
|
Family Characteristics | 1 | 2019 | 1000 | 0.120 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2017 | 714 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2009 | 855 | 0.120 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3614 | 0.120 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9163 | 0.120 |
Why?
|
Treatment Outcome | 6 | 2024 | 64242 | 0.110 |
Why?
|
Lymphocytes | 1 | 2021 | 2610 | 0.110 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 1017 | 0.110 |
Why?
|
Genetic Heterogeneity | 1 | 2016 | 723 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6894 | 0.100 |
Why?
|
Quinazolines | 1 | 2018 | 1371 | 0.100 |
Why?
|
Protein Conformation | 1 | 2009 | 3966 | 0.100 |
Why?
|
Benzamides | 3 | 2022 | 1363 | 0.100 |
Why?
|
Models, Molecular | 1 | 2021 | 5406 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3480 | 0.090 |
Why?
|
Piperazines | 1 | 2021 | 2511 | 0.090 |
Why?
|
Melanoma | 4 | 2020 | 5689 | 0.090 |
Why?
|
Indazoles | 2 | 2022 | 302 | 0.090 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 373 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6292 | 0.080 |
Why?
|
Biopsy | 1 | 2021 | 6757 | 0.080 |
Why?
|
rab GTP-Binding Proteins | 1 | 2010 | 250 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3756 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2022 | 2326 | 0.080 |
Why?
|
Microphthalmia-Associated Transcription Factor | 2 | 2010 | 259 | 0.080 |
Why?
|
Janus Kinase 2 | 1 | 2011 | 537 | 0.080 |
Why?
|
GTPase-Activating Proteins | 1 | 2010 | 474 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39020 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2524 | 0.070 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 869 | 0.070 |
Why?
|
Activating Transcription Factor 1 | 1 | 2006 | 26 | 0.070 |
Why?
|
Prognosis | 4 | 2021 | 29488 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8512 | 0.060 |
Why?
|
Sarcoma, Clear Cell | 1 | 2006 | 72 | 0.060 |
Why?
|
RNA-Binding Protein EWS | 1 | 2006 | 210 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10167 | 0.060 |
Why?
|
Animals | 6 | 2019 | 167718 | 0.050 |
Why?
|
Survival Analysis | 1 | 2015 | 10075 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8815 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2010 | 2318 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6840 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11709 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 326 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2015 | 20992 | 0.040 |
Why?
|
Tumor Stem Cell Assay | 1 | 2009 | 115 | 0.040 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5786 | 0.040 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2859 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18114 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 628 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 705 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 310 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10135 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 607 | 0.040 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 51 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3521 | 0.040 |
Why?
|
Mice | 4 | 2019 | 81066 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 852 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20499 | 0.030 |
Why?
|
Brain | 1 | 2023 | 26952 | 0.030 |
Why?
|
Gene Expression Profiling | 4 | 2015 | 9403 | 0.030 |
Why?
|
Indoles | 1 | 2024 | 1824 | 0.030 |
Why?
|
Mutagenesis | 1 | 2009 | 1233 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2018 | 390 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2015 | 164 | 0.030 |
Why?
|
Imidazoles | 1 | 2021 | 1178 | 0.030 |
Why?
|
Cell Fusion | 1 | 2015 | 293 | 0.030 |
Why?
|
Ligands | 1 | 2021 | 3257 | 0.030 |
Why?
|
Signal Transduction | 3 | 2011 | 23335 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1342 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2022 | 1882 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1994 | 0.030 |
Why?
|
Transcription Factors | 3 | 2023 | 12092 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6128 | 0.030 |
Why?
|
Transfection | 1 | 2020 | 5777 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2009 | 2564 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 5778 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6470 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3573 | 0.020 |
Why?
|
Epigenomics | 1 | 2015 | 936 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2006 | 9574 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2009 | 4710 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2495 | 0.020 |
Why?
|
Base Sequence | 1 | 2009 | 12437 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2020 | 2195 | 0.020 |
Why?
|
Protein Binding | 1 | 2009 | 9312 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8426 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5788 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4550 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 17615 | 0.020 |
Why?
|
Melanocyte-Stimulating Hormones | 1 | 2006 | 25 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11082 | 0.020 |
Why?
|
SOXE Transcription Factors | 1 | 2006 | 73 | 0.020 |
Why?
|
High Mobility Group Proteins | 1 | 2006 | 177 | 0.020 |
Why?
|
Protein Transport | 1 | 2010 | 1963 | 0.020 |
Why?
|
Adolescent | 2 | 2022 | 87819 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8503 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 9245 | 0.010 |
Why?
|
Child | 2 | 2022 | 79782 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2006 | 316 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2009 | 1114 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2009 | 3593 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2378 | 0.010 |
Why?
|
Melanocytes | 1 | 2006 | 509 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8946 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7584 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2006 | 2013 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3432 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2011 | 3206 | 0.010 |
Why?
|
Mice, Nude | 1 | 2006 | 3600 | 0.010 |
Why?
|
Cell Survival | 1 | 2009 | 5781 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 54092 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41190 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 10405 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2006 | 11469 | 0.000 |
Why?
|